AstraZeneca and Merck & Co., Inc., announced that they were granted orphan drug designation by the US Food and Drug Administration (FDA) for Lynparza for the treatment of pancreatic cancer.
Pancreatic cancer is a rare, life-threatening disease that accounts for about 3 percent of all cancers in the US.i Due to the late onset of symptoms, patients are often diagnosed after cancer has progressed to locally advanced or metastatic stages of the disease.
Five-year survival rates remain low in the US at 8.5%.
Sean Bohen, executive vice president, Global Medicines Development and chief medical officer said: “Pancreatic cancer is an area of significant unmet medical need. This is especially true for patients with metastatic disease where the benefits of current treatment options are very limited.”
Orphan Drug status was granted for the treatment of ovarian cancer in October 2013. Earlier this year an amended ODD status was granted to include both fallopian tube and primary peritoneal cancers following the expanded US approval of Lynparza in August 2017 for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy, an AZ release noted.
The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.
The use of Lynparza in pancreatic cancer is being assessed in the ongoing Phase III POLO trial, which is testing Lynparza as maintenance monotherapy vs placebo in some patients.
AstraZeneca employs 1,500 in Delaware.
